Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from May 10, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 8, 2026.
Predicted vs. what happened
AUPH price · publication thesis → realized outcomesplit-adjusted
$14.50 – $15.40Entry zone — fair-value band
$15.23Published — price the day we called it
$17.06Target — the price the thesis aimed for
$19.25Peak — highest point inside the window, not a realized return
$15.85Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 43 days.
Peak price
$19.25
peak on June 24, 2026 — not a realized returnPeak gain
+26.4%
peak, from the publication priceWindow close
$15.85
end-of-window price, context onlyDays to target
43
Window
May 10, 2026 – August 8, 2026
The thesis — published May 10, 2026
Predicted growth
+12%
over the measurement windowTarget price
$17.06
the price the thesis aimed forEntry zone
$14.50 – $15.40
the fair-value band we waited forPrice at publication
$15.23
published May 10, 2026Confidence
74%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Aurinia looks like a value play: it has solid cash, company insiders buying, and recent results that help a rebound case. However, public news isn't focused on the company, which makes near-term confidence weaker. The short-term setup looks constructive if prescription and payment trends stay steady and price momentum steadies from support.
Primary drivers
- Strong cash position lowers need for new funding
- Insider buying signals confidence from management
- Recent reported results support a recovery case
- Oversold price action increases chance of a rebound
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.